WEST LAFAYETTE, Ind. – Vancomycin-resistant enterococcus (VRE) is among the leading causes of hospital-acquired infections in the United States. An estimated 20,000 people in the U.S. become infected ...

A drug-resistant strain of bacteria inhabiting hospital settings has evolved to utilize an antimicrobial genetic tool. Vancomycin-resistant Enterococcus faecium (VREfm) is responsible for many lethal ...

Please provide your email address to receive an email when new articles are posted on . Clinical response was noted in 47.6% of patients treated with oral vancomycin therapy for IBD associated with ...

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization. A recent study has demonstrated ...

Antibiotic resistance is a major concern, particularly for immunocompromised patients, who are at greater risk of serious infections. Microbiota composition can help prevent pathogenic bacteria from ...

The incidence of enterococcal infections has been increasing over the past few years, with rising rates of multidrug resistance. VRE is increasingly a problem in many hospitals and intensive care ...

The scientists replaced a single atom from the molecular structure of vancomycin aglycon, a glycopeptide antibiotic that attacks the bacteria by inhibiting cell wall synthesis, significantly ...

A drug-resistant type of bacteria that has adapted to health care settings evolved in the past several years to weaponize an antimicrobial genetic tool, eliminating its cousins and replacing them as ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...